420 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Acquired by Flaharty Asset Management LLC

Flaharty Asset Management LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 420 shares of the medical research company’s stock, valued at approximately $212,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. Exencial Wealth Advisors LLC boosted its stake in Thermo Fisher Scientific by 9.7% in the 1st quarter. Exencial Wealth Advisors LLC now owns 892 shares of the medical research company’s stock valued at $407,000 after purchasing an additional 79 shares during the period. Jackson Hole Capital Partners LLC boosted its stake in Thermo Fisher Scientific by 46.1% in the 1st quarter. Jackson Hole Capital Partners LLC now owns 872 shares of the medical research company’s stock valued at $398,000 after purchasing an additional 275 shares during the period. Sowell Financial Services LLC lifted its position in shares of Thermo Fisher Scientific by 46.8% during the 1st quarter. Sowell Financial Services LLC now owns 13,925 shares of the medical research company’s stock valued at $6,546,000 after acquiring an additional 4,439 shares during the period. Meridian Wealth Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 82.3% during the 1st quarter. Meridian Wealth Advisors LLC now owns 516 shares of the medical research company’s stock valued at $236,000 after acquiring an additional 233 shares during the period. Finally, Meridian Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 152.3% during the 1st quarter. Meridian Wealth Management LLC now owns 2,720 shares of the medical research company’s stock valued at $1,241,000 after acquiring an additional 1,642 shares during the period. Institutional investors and hedge funds own 85.50% of the company’s stock.

Shares of TMO traded up $5.99 on Tuesday, reaching $596.19. 2,395 shares of the company’s stock traded hands, compared to its average volume of 1,609,678. The company has a current ratio of 2.78, a quick ratio of 2.11 and a debt-to-equity ratio of 0.51. The stock has a market cap of $234.55 billion, a PE ratio of 27.36, a PEG ratio of 1.33 and a beta of 0.74. The stock’s 50 day simple moving average is $546.75 and its two-hundred day simple moving average is $497.57. Thermo Fisher Scientific Inc. has a 52-week low of $412.80 and a 52-week high of $609.30.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 28th. The medical research company reported $5.60 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $5.51 by $0.09. Thermo Fisher Scientific had a return on equity of 29.43% and a net margin of 22.47%. The business had revenue of $9.27 billion during the quarter, compared to the consensus estimate of $8.75 billion. Analysts forecast that Thermo Fisher Scientific Inc. will post 22.07 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, October 15th. Shareholders of record on Wednesday, September 15th will be given a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a yield of 0.17%. The ex-dividend date is Tuesday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 5.32%.

In other news, Director Jim P. Manzi sold 572 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 30th. The stock was sold at an average price of $536.54, for a total value of $306,900.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 4th. The shares were sold at an average price of $539.05, for a total value of $5,390,500.00. The disclosure for this sale can be found here. 0.44% of the stock is currently owned by insiders.

TMO has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their target price on Thermo Fisher Scientific from $600.00 to $700.00 and gave the company an “overweight” rating in a research report on Monday. Jefferies Financial Group assumed coverage on Thermo Fisher Scientific in a research report on Monday. They set a “hold” rating and a $540.00 price objective for the company. Argus upped their price objective on Thermo Fisher Scientific from $530.00 to $600.00 and gave the stock a “buy” rating in a research report on Wednesday, August 4th. The Goldman Sachs Group dropped their price objective on Thermo Fisher Scientific from $590.00 to $530.00 and set a “buy” rating for the company in a research report on Tuesday, June 15th. They noted that the move was a valuation call. Finally, BTIG Research upped their target price on Thermo Fisher Scientific from $590.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, July 29th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Buy” and an average price target of $580.43.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Read More: What is the CBOE Russell 2000® Volatility Index?

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.